Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous anti-siglec-6 CAR-T cells

A preparation of autologous T lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) targeting sialic acid-binding immunoglobulin (Ig)-like lectin 6 (Siglec-6) and containing, as of yet undisclosed co-stimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon infusion back into the patient, autologous anti-Siglec-6 CAR-T cells target and bind to Siglec-6-expressing tumor cells, thereby inducing selective toxicity in Siglec-6-expressing tumor cells. Siglec-6 is overexpressed in certain malignancies, including acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL), and not expressed in normal hematopoietic stem and progenitor cells (HSPCs).
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-Siglec-6 CAR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search